INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclon...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2255 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400188449325056 |
|---|---|
| author | Sh. F. Erdes |
| author_facet | Sh. F. Erdes |
| author_sort | Sh. F. Erdes |
| collection | DOAJ |
| description | Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclonal antibodies (secukinumab) has emerged, which allows expanding therapeutic opportunities for this disease. Trials have shown that secukinumab is effective in treating AS, has low immunogenicity and its safety profile does not virtually differ from that of placebo. |
| format | Article |
| id | doaj-art-5cebc76ea6034c1b88c4d4689b15c01b |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2016-09-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-5cebc76ea6034c1b88c4d4689b15c01b2025-08-20T03:38:09ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-09-01541S606610.14412/1995-4484-2016-1S-60-662123INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITISSh. F. Erdes0V.A. Nasonova Research Institute of Rheumatology, MoscowTherapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclonal antibodies (secukinumab) has emerged, which allows expanding therapeutic opportunities for this disease. Trials have shown that secukinumab is effective in treating AS, has low immunogenicity and its safety profile does not virtually differ from that of placebo.https://rsp.mediar-press.net/rsp/article/view/2255ankylosing spondylitisinterleukin-17secukinumab |
| spellingShingle | Sh. F. Erdes INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS Научно-практическая ревматология ankylosing spondylitis interleukin-17 secukinumab |
| title | INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
| title_full | INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
| title_fullStr | INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
| title_full_unstemmed | INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
| title_short | INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
| title_sort | interleukin 17a is a new target of anticytokine therapy for ankylosing spondylitis |
| topic | ankylosing spondylitis interleukin-17 secukinumab |
| url | https://rsp.mediar-press.net/rsp/article/view/2255 |
| work_keys_str_mv | AT shferdes interleukin17aisanewtargetofanticytokinetherapyforankylosingspondylitis |